285 related articles for article (PubMed ID: 17883284)
1. Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease.
Andress D
Drugs; 2007; 67(14):1999-2012. PubMed ID: 17883284
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.
Brancaccio D; Bommer J; Coyne D
Drugs; 2007; 67(14):1981-98. PubMed ID: 17883283
[TBL] [Abstract][Full Text] [Related]
3. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
Cozzolino M; Brancaccio D
Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effects of selective vitamin D receptor activation by paricalcitol in chronic kidney disease.
Donate-Correa J; Domínguez-Pimentel V; Muros-de-Fuentes M; Mora-Fernández C; Martín-Núñez E; Cazaña-Pérez V; Navarro-González JF
Curr Drug Targets; 2014; 15(7):703-9. PubMed ID: 24745821
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D receptor activation, left ventricular hypertrophy and myocardial fibrosis.
Panizo S; Barrio-Vázquez S; Naves-Díaz M; Carrillo-López N; Rodríguez I; Fernández-Vázquez A; Valdivielso JM; Thadhani R; Cannata-Andía JB
Nephrol Dial Transplant; 2013 Nov; 28(11):2735-44. PubMed ID: 24013683
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of paricalcitol in patients with chronic kidney disease.
Dyer CA
Expert Opin Drug Saf; 2013 Sep; 12(5):717-28. PubMed ID: 23621417
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats.
Noonan W; Koch K; Nakane M; Ma J; Dixon D; Bolin A; Reinhart G
Nephrol Dial Transplant; 2008 Dec; 23(12):3824-30. PubMed ID: 18644798
[TBL] [Abstract][Full Text] [Related]
8. Comparison between paricalcitol and active non-selective vitamin D receptor activator for secondary hyperparathyroidism in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.
Cai P; Tang X; Qin W; Ji L; Li Z
Int Urol Nephrol; 2016 Apr; 48(4):571-84. PubMed ID: 26748501
[TBL] [Abstract][Full Text] [Related]
9. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism.
Akizawa T; Akiba T; Hirakata H; Kinugasa E; Tominaga Y; Fukagawa M; Yokoyama K; Zhang W; Linde PG; Suzuki M
Ther Apher Dial; 2015 Jun; 19(3):225-34. PubMed ID: 25363733
[TBL] [Abstract][Full Text] [Related]
10. [Paricalcitol - a selective vitamin D receptor activator for secondary hyperparathyroidism in patients with chronic kidney disease].
Matuszkiewicz-Rowińska J; Żebrowski P
Wiad Lek; 2016; 69(5):756-759. PubMed ID: 28033603
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials.
Xie Y; Su P; Sun Y; Zhang H; Zhao R; Li L; Meng L
BMC Nephrol; 2017 Aug; 18(1):272. PubMed ID: 28841848
[TBL] [Abstract][Full Text] [Related]
12. Vascular calcification in chronic kidney failure: role of vitamin D receptor.
Wu-Wong JR; Melnick J
Curr Opin Investig Drugs; 2007 Mar; 8(3):237-47. PubMed ID: 17408120
[TBL] [Abstract][Full Text] [Related]
13. Secondary hyperparathyroidism in chronic dialysis patients: results of the Italian FARO survey on treatment and mortality.
Brancaccio D; Cozzolino M; Cannella G; Messa P; Bonomini M; Cancarini G; Caruso MR; Cascone C; Costanzo AM; di Luzio Paparatti U; Mazzaferro S;
Blood Purif; 2011; 32(2):124-32. PubMed ID: 21625082
[TBL] [Abstract][Full Text] [Related]
14. New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor activators.
Brancaccio D; Cozzolino M; Pasho S; Fallabrino G; Olivi L; Gallieni M
Contrib Nephrol; 2009; 163():219-226. PubMed ID: 19494617
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients.
Sprague SM; Covic AC; Floege J; Ketteler M; Botha J; Chong EM; Rastogi A
Am J Nephrol; 2016; 44(2):104-12. PubMed ID: 27434393
[TBL] [Abstract][Full Text] [Related]
16. Paricalcitol and outcome: a manual on how a vitamin D receptor activator (VDRA) can help us to get down the "U".
Cozzolino M; Brandenburg V
Clin Nephrol; 2009 Jun; 71(6):593-601. PubMed ID: 19473626
[TBL] [Abstract][Full Text] [Related]
17. Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients.
Shinaberger CS; Kopple JD; Kovesdy CP; McAllister CJ; van Wyck D; Greenland S; Kalantar-Zadeh K
Clin J Am Soc Nephrol; 2008 Nov; 3(6):1769-76. PubMed ID: 18701614
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D analogues for the management of secondary hyperparathyroidism.
Martin KJ; González EA
Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D receptor agonist VS-105 directly modulates parathyroid hormone expression in human parathyroid cells and in 5/6 nephrectomized rats.
Sawada K; Wu-Wong JR; Chen YW; Wessale JL; Kanai G; Kakuta T; Fukagawa M
J Steroid Biochem Mol Biol; 2017 Mar; 167():48-54. PubMed ID: 27989797
[TBL] [Abstract][Full Text] [Related]
20. A comparative analysis of the efficacy and safety of paricalcitol versus other vitamin D receptor activators in patients undergoing hemodialysis: A systematic review and meta-analysis of 15 randomized controlled trials.
Geng X; Shi E; Wang S; Song Y
PLoS One; 2020; 15(5):e0233705. PubMed ID: 32470067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
